Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 28, 2017

Chiesi, Molecular Warehouse partner to develop diagnostic system for transplant patients

Italy-based healthcare group Chiesi Pharmaceuticals has partnered with UK-based medical diagnostics start up Molecular Warehouse (MW) to create a diagnostic tool for transplant patients.

Italy-based healthcare group Chiesi Pharmaceuticals has partnered with UK-based medical diagnostics start up Molecular Warehouse (MW) to create a diagnostic tool for transplant patients.

The new diagnostic system will aim at enabling patients to remotely monitor their immunosuppressant levels.

Monitoring is required for immunosuppressant drugs such as Envarsus (tacrolimus prolonged release) taken by patients to prevent organ rejection after receiving a graft from a donor.

"The partnership is expected to result in a system that will allow patients to self-test at home, by utilising an easy to use finger-prick blood test which is connected to their smartphone."

It is to ensure that the levels of these drugs in the patient’s bloodstream are in a range that decreases the reactivity of the immune system to avoid rejection, but does not expose the patient to an increased risk of infections.

Chiesi chief executive officer Ugo Di Francesco said: “We believe MW’s innovative diagnostic system could reduce the impact of this necessary inconvenience for the patients and their doctors, while enabling even more frequent monitoring of drug levels, potentially improving patient care."

The research and developement collaboration with MW is a part of Chiesi's strategy to combine digital innovation, disease management and patient care with therapeutic options.

Content from our partners
Clinical Evaluation Report template: a free resource for medical device manufacturers
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The partnership is expected to result in a system that will allow patients to self-test at home, by utilising an easy to use finger-prick blood test which is connected to their smartphone.

The test results will be automatically communicated with the patient's specialist.

MW chief executive officer Dr Siro Perez said: “The remote monitoring of immunosuppressants is technically a very complex problem, and we are applying cutting edge technologies from the fields of electronics, synthetic biology, and software to develop this diagnostic test."

By creating this new tool, the firms intend to eliminate the need for regular patient visits to undertake a blood test for immunosuppressants.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU